Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia

Authors:

Abstract
No abstract available
Funding Information
  • Regione Campania (DGRC 2362/07)
  • MIUR (PS 35-126/Ind)

This publication has 29 references indexed in Scilit: